Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

BACKGROUND. The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma. ABT-414 is a first-in-class, tumor-specific antibody-drug conjugate that...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Neuro Oncol
Autori principali: Reardon, David A., Lassman, Andrew B., van den Bent, Martin, Kumthekar, Priya, Merrell, Ryan, Scott, Andrew M., Fichtel, Lisa, Sulman, Erik P., Gomez, Erica, Fischer, JuDee, Lee, Ho-Jin, Munasinghe, Wijith, Xiong, Hao, Mandich, Helen, Roberts-Rapp, Lisa, Ansell, Peter, Holen, Kyle D., Gan, Hui K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2017
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570193/
https://ncbi.nlm.nih.gov/pubmed/28039367
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now257
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi